Cancer stem cell subsets and their relationships

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Liu, Hai Guang ^a   Chen, Chong ^a   Yang, Han ^a   Pan, Yi Fei ^a   Zhang, Xiao Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ERLOTINIB; FLUOROURACIL; HERMES ANTIGEN; OXALIPLATIN; THY 1 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL RENEWAL; CELL SUBPOPULATION; CELL TRANSFORMATION; EMBRYONIC STEM CELL; HUMAN; INTRADUCTAL CARCINOMA; NONHUMAN; PRECANCER; PROTEIN EXPRESSION; REVIEW; ANIMAL; ARTICLE; CELL MOTION; DRUG RESISTANCE; PATHOLOGY; RADIATION DOSE;

ANIMALS; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS; RADIATION TOLERANCE;

EID: 79955493691     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-50     Document Type: Review

References (107)

1. La Porta C. Cancer stem cells: lessons from melanoma. Stem Cell Rev 2009, 5(1):61-5. 10.1007/s12015-008-9048-7, 19093230.
2. Rajan P, Srinivasan R. Targeting cancer stem cells in cancer prevention and therapy. Stem Cell Rev 2008, 4(3):211-6. 10.1007/s12015-008-9037-x, 18663609.
3. Sales K, Winslet M, Seifalian A. Stem cells and cancer: an overview. Stem Cell Rev 2007, 3(4):249-55. 10.1007/s12015-007-9002-0, 17955391.
4. Huntly B, Gilliland D. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5(4):311-21. 10.1038/nrc1592, 15803157.
5. Bruce W, Van der Gaag H. A QUANTITATIVE ASSAY FOR THE NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO. Nature 1963, 199:79-80. 10.1038/199079a0, 14047954.
6. Becker A, McCulloch E, Till J. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963, 197:452-4. 10.1038/197452a0, 13970094.
7. Park C, Bergsagel D, McCulloch E. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971, 46(2):411-22.
8. Hamburger A, Salmon S. Primary bioassay of human tumor stem cells. Science 1977, 197(4302):461-3. 10.1126/science.560061, 560061.
9. Bonner W, Hulett H, Sweet R, et al. Fluorescence activated cell sorting. Rev Sci Instrum 1972, 43(3):404-9. 10.1063/1.1685647, 5013444.
10. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-7. 10.1038/nm0797-730, 9212098.
11. Al-Hajj M, Wicha M, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-8. 10.1073/pnas.0530291100, 153034, 12629218.
12. Jordan C. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002, 16(4):559-62. 10.1038/sj.leu.2402446, 11960332.
13. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5(1):31-42. 10.1016/j.stem.2009.04.018, 19570512.
14. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138(2):286-99. 10.1016/j.cell.2009.05.045, 2726837, 19632179.
15. Bauerschmitz G, Ranki T, Kangasniemi L, et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008, 68(14):5533-9. 10.1158/0008-5472.CAN-07-5288, 18632604.
16. Ginestier C, Hur M, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(5):555-67. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
17. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010, 16(1):45-55. 10.1158/1078-0432.CCR-09-1630, 2874875, 20028757.
18. Singh S, Clarke I, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63(18):5821-8.
19. Singh S, Hawkins C, Clarke I, et al. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401. 10.1038/nature03128, 15549107.
20. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64(19):7011-21. 10.1158/0008-5472.CAN-04-1364, 15466194.
21. Son M, Woolard K, Nam D, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4(5):440-52. 10.1016/j.stem.2009.03.003, 19427293.
22. Tchoghandjian A, Baeza N, Colin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 2010, 20(1):211-21. 10.1111/j.1750-3639.2009.00269.x, 19243384.
23. Collins A, Berry P, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65(23):10946-51. 10.1158/0008-5472.CAN-05-2018, 16322242.
24. Mulholland D, Xin L, Morim A, et al. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 2009, 69(22):8555-62. 10.1158/0008-5472.CAN-08-4673, 2783355, 19887604.
25. Su Y, Qiu Q, Zhang X, et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010, 19(2):327-37. 10.1158/1055-9965.EPI-09-0865, 20142235.
26. Kim C, Jackson E, Woolfenden A, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121(6):823-35. 10.1016/j.cell.2005.03.032, 15960971.
27. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15(3):504-14. 10.1038/sj.cdd.4402283, 18049477.
28. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7(3):330-8. 10.1158/1541-7786.MCR-08-0393, 19276181.
29. Fang D, Nguyen T, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65(20):9328-37. 10.1158/0008-5472.CAN-05-1343, 16230395.
30. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43(5):935-46. 10.1016/j.ejca.2007.01.017, 17320377.
31. Keshet G, Goldstein I, Itzhaki O, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 2008, 368(4):930-6. 10.1016/j.bbrc.2008.02.022, 18279661.
32. Schatton T, Murphy G, Frank N, et al. Identification of cells initiating human melanomas. Nature 2008, 451(7176):345-9. 10.1038/nature06489, 18202660.
33. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466(7302):133-7. 10.1038/nature09161, 2898751, 20596026.
34. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141(4):583-94. 10.1016/j.cell.2010.04.020, 20478252.
35. O'Brien C, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445(7123):106-10. 10.1038/nature05372, 17122772.
36. Ricci-Vitiani L, Lombardi D, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445(7123):111-5. 10.1038/nature05384, 17122771.
37. Shmelkov S, Butler J, Hooper A, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118(6):2111-20. 2391278, 18497886.
38. LaBarge M, Bissell M. Is CD133 a marker of metastatic colon cancer stem cells?. J Clin Invest 2008, 118(6):2021-4. 2391070, 18497883.
39. Barker N, van Es J, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449(7165):1003-7. 10.1038/nature06196, 17934449.
40. Huang E, Hynes M, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69(8):3382-9. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
41. Dalerba P, Dylla S, Park I, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104(24):10158-63. 10.1073/pnas.0703478104, 1891215, 17548814.
42. Pang R, Law W, Chu A, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6(6):603-15. 10.1016/j.stem.2010.04.001, 20569697.
43. Zhu L, Gibson P, Currle D, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457(7229):603-7. 10.1038/nature07589, 2633030, 19092805.
44. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-7. 10.1158/0008-5472.CAN-06-2030, 17283135.
45. Hermann P, Huber S, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-23. 10.1016/j.stem.2007.06.002, 18371365.
46. Prince M, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104(3):973-8. 10.1073/pnas.0610117104, 1783424, 17210912.
47. Chen Y, Chen Y, Hsu H, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385(3):307-13. 10.1016/j.bbrc.2009.05.048, 19450560.
48. Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22(6):1207-13. 10.1038/leu.2008.83, 18418410.
49. Zhang S, Balch C, Chan M, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68(11):4311-20. 10.1158/0008-5472.CAN-08-0364, 2553722, 18519691.
50. Baba T, Convery P, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28(2):209-18. 10.1038/onc.2008.374, 18836486.
51. Rutella S, Bonanno G, Procoli A, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009, 15(13):4299-311. 10.1158/1078-0432.CCR-08-1883, 19509143.
52. Yang Z, Ho D, Ng M, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13(2):153-66. 10.1016/j.ccr.2008.01.013, 18242515.
53. Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351(4):820-4. 10.1016/j.bbrc.2006.10.128, 17097610.
54. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010, 52(2):280-1. 10.1016/j.jhep.2009.10.026, 20006402.
55. Bussolati B, Bruno S, Grange C, et al. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008, 22(10):3696-705. 10.1096/fj.08-102590, 18614581.
56. Read T, Fogarty M, Markant S, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15(2):135-47. 10.1016/j.ccr.2008.12.016, 2664097, 19185848.
57. Ward R, Lee L, Graham K, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res 2009, 69(11):4682-90. 10.1158/0008-5472.CAN-09-0342, 19487286.
58. Takaishi S, Okumura T, Tu S, et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44. Stem Cells 2009, 27(5):1006-1020. 10.1002/stem.30, 2746367, 19415765.
59. Levings P, McGarry S, Currie T, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009, 69(14):5648-55. 10.1158/0008-5472.CAN-08-3580, 2841219, 19584295.
60. Xu Q, Yuan X, Tunici P, et al. Isolation of tumour stem-like cells from benign tumours. Br J Cancer 2009, 101(2):303-11. 10.1038/sj.bjc.6605142, 2720199, 19568241.
61. Chen L, Shen R, Ye Y, et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE 2007, 2(3):e293. 10.1371/journal.pone.0000293, 1808425, 17356702.
62. Shen R, Ye Y, Chen L, et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE 2008, 3(2):e1652. 10.1371/journal.pone.0001652, 2242848, 18286204.
63. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-67. 10.1016/0092-8674(90)90186-I, 2188735.
64. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135(4):1079-99. 10.1053/j.gastro.2008.07.076, 2866182, 18773902.
65. Bae KM, Su Z, Frye C, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010, 183(5):2045-53. 10.1016/j.juro.2009.12.092, 20303530.
66. Damonte P, Hodgson J, Chen J, et al. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res 2008, 10(3):R50. 10.1186/bcr2104, 2481504, 18522749.
67. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ?". Nat Rev Cancer 2011, 11(1):68-75. 10.1038/nrc2950, 21150936.
68. Castro NP, Osório CA, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008, 10(5):R87. 10.1186/bcr2157, 2614523, 18928525.
69. Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11(1):R7. 10.1186/bcr2222, 2687710, 19187537.
70. Shen R, Tao L, Xu Y, et al. Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer. Int J Clin Exp Pathol 2009, 2(1):21-33. 2491387, 18830381.
71. Wang X, Kruithof-de Julio M, Economides K, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461(7263):495-500. 10.1038/nature08361, 2800362, 19741607.
72. Barker N, Ridgway R, van Es J, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457(7229):608-11. 10.1038/nature07602, 19092804.
73. Røsland G, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009, 69(13):5331-9. 10.1158/0008-5472.CAN-08-4630, 19509230.
74. Werbowetski-Ogilvie T, Bossé M, Stewart M, et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 2009, 27(1):91-7. 10.1038/nbt.1516, 19122652.
75. Jamieson C, Ailles L, Dylla S, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351(7):657-67. 10.1056/NEJMoa040258, 15306667.
76. Minami Y, Stuart S, Ikawa T, et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008, 105(46):17967-72. 10.1073/pnas.0808303105, 2582213, 19004799.
77. Stuart S, Minami Y, Wang J. The CML stem cell: evolution of the progenitor. Cell Cycle 2009, 8(9):1338-43. 10.4161/cc.8.9.8209, 2792634, 19342894.
78. Guibal F, Alberich-Jorda M, Hirai H, et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009, 114(27):5415-25. 10.1182/blood-2008-10-182071, 2798860, 19797526.
79. Krivtsov A, Feng Z, Armstrong S. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci 2009, 1176:144-9. 10.1111/j.1749-6632.2009.04966.x, 19796242.
80. Dick J. Looking ahead in cancer stem cell research. Nat Biotechnol 2009, 27(1):44-6. 10.1038/nbt0109-44, 19131997.
81. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-76. 10.1016/j.cell.2006.07.024, 16904174.
82. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322(5903):949-53. 10.1126/science.1164270, 18845712.
83. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008, 322(5903):945-9. 10.1126/science.1162494, 18818365.
84. Yu JY, Hu KJ, Smuga-Otto K, et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science 2009, 324(5928):797-801. 10.1126/science.1172482, 2758053, 19325077.
85. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458(7239):771-5. 10.1038/nature07864, 2667910, 19252477.
86. Lyssiotis C, Foreman R, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009, 106(22):8912-7. 10.1073/pnas.0903860106, 2690053, 19447925.
87. Zhou H, Wu S, Joo J, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4(5):381-4. 10.1016/j.stem.2009.04.005, 19398399.
88. Kim D, Kim C, Moon J, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4(6):472-6. 10.1016/j.stem.2009.05.005, 2705327, 19481515.
89. Li W, Wei W, Zhu S, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009, 4(1):16-9. 10.1016/j.stem.2008.11.014, 19097958.
90. Weigelt B, Peterse J, van't Veer L. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5(8):591-602. 10.1038/nrc1670, 16056258.
91. Fidler I. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-8. 10.1038/nrc1098, 12778135.
92. Hart I, Fidler I. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40(7):2281-7.
93. Mani S, Guo W, Liao M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-15. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
94. Zhang D, LaFortune T, Krishnamurthy S, et al. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 2009, 15(21):6639-48. 10.1158/1078-0432.CCR-09-0951, 2783487, 19825949.
95. McCoy E, Iwanaga R, Jedlicka P, et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 2009, 119(9):2663-77. 10.1172/JCI37691, 2735909, 19726883.
96. Radisky D. Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest 2009, 119(9):2528-31. 10.1172/JCI40555, 2735897, 19726879.
97. Liu M, Casimiro M, Wang C, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009, 106(45):19035-9. 10.1073/pnas.0910009106, 2776463, 19858489.
98. Todaro M, Alea M, Di Stefano A, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1(4):389-402. 10.1016/j.stem.2007.08.001, 18371377.
99. Todaro M, Perez Alea M, Scopelliti A, et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7(3):309-13. 10.4161/cc.7.3.5389, 18235245.
100. Francipane M, Alea M, Lombardo Y, et al. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 2008, 68(11):4022-5. 10.1158/0008-5472.CAN-07-6874, 18519657.
101. Eckford P, Sharom F. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109(7):2989-3011. 10.1021/cr9000226, 19583429.
102. Fletcher J, Haber M, Henderson M, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10(2):147-56. 10.1038/nrc2789, 20075923.
103. Ding X, Wu J, Jiang C. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010, 86(17-18):631-7. 10.1016/j.lfs.2010.02.012, 20159023.
104. Shukla S, Wu C, Ambudkar S. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008, 4(2):205-23. 10.1517/17425255.4.2.205, 18248313.
105. Diehn M, Cho R, Lobo N, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458(7239):780-3. 10.1038/nature07733, 2778612, 19194462.
106. Lomonaco S, Finniss S, Xiang C, et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125(3):717-22. 10.1002/ijc.24402, 19431142.
107. Phillips T, McBride W, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-85. 10.1093/jnci/djj495, 17179479.